Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy : for suppression of lymph node and distant metastasis in a murine melanoma model

Sasaki, Yuki; Maeda, Taku; Hojo, Masahiro; Miura, Takahiro; Ishikawa, Kosuke; Funayama, Emi; Okada, Kazufumi; Yamamoto, Yuhei

Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy : for suppression of lymph node and distant metastasis in a murine melanoma model

Sasaki, Yuki; Maeda, Taku; Hojo, Masahiro et al.

Biochemical and biophysical research communications, 2024, 740, 151011

Permalink : https://hdl.handle.net/2115/97322

このアイテムのアクセス数:46件（2026-07-14 03:48 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
HUSCAP_BBRC-24-6321_R2	pdf	3.60 MB	35

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/97322
タイトル	Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy : for suppression of lymph node and distant metastasis in a murine melanoma model
著者	Sasaki, Yuki ; Maeda, Taku ; Hojo, Masahiro ; Miura, Takahiro ; Ishikawa, Kosuke ; Funayama, Emi ; Okada, Kazufumi ; Yamamoto, Yuhei
e-Rad_Researcher 00923369 著者名 Sasaki, Yuki
e-Rad_Researcher 80813542 著者名 Maeda, Taku
e-Rad_Researcher 80866666 著者名 Hojo, Masahiro
e-Rad_Researcher 90829433 著者名 Miura, Takahiro
e-Rad_Researcher 60791374 著者名 Ishikawa, Kosuke
e-Rad_Researcher 10533630 著者名 Funayama, Emi
著者名 Okada, Kazufumi
e-Rad_Researcher 70271674 著者名 Yamamoto, Yuhei
言語	英語
キーワード	Cutaneous malignant melanoma
	Oncolytic viruses
	Lymphatic system
	Mice
	Combination drug therapy
	Immunologic adjuvants
発行日	2024-11-17
出版者	Elsevier
収録物名	Biochemical and biophysical research communications
巻(号)	740
ページ	151011
抄録	It is believed that oncolytic viruses (OVs) exert both direct anti-tumor effects by intratumoral injection as well as indirect anti-tumor effects by activating systemic immunity. In phase III clinical trials, OV and anti-programmed cell death-1 (aPD-1) antibody combination therapy showed no significant differences in overall survival and progression-free survival in patients with unresectable advanced melanoma. In the study, OVs can exert only indirect anti-tumor effects in non-injected, systemic lesions. If the tumor is at a stage where both direct and indirect anti-tumor effects of OVs can be expected, OVs may further enhance the therapeutic effect, in addition to the clinically expected therapeutic effect. Therefore, we investigated whether canerpaturev (C-REV) and aPD-1 antibody combination therapy suppresses tumor progression in a murine melanoma model. Our findings showed that the C-REV and aPD-1 antibody combination therapy suppressed tumor progression in a murine melanoma model. The combination therapy stimulated systemic immunity in lymphoid tissues by activating helper T cells and B cells to enhance adaptive and humoral immunity, as well as by increasing effector/memory T cell fractions. Synergistically enhanced systemic anti-tumor effects suppressed lymph node and lung metastases. These findings suggest that direct anti-tumor effects by infecting and destroying cancer cells from within and indirect anti-tumor effects enhanced by the combination therapy worked simultaneously to suppress tumor progression. Our results may provide evidence to support the usefulness of OV and aPD-1 antibody combination therapy as a neoadjuvant therapy in the surgical treatment of melanoma.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0006-291X
EISSN	1090-2104
関連情報	PMID 39571230
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.bbrc.2024.151011